Abstract Following the first characterization of circulating tumor DNA (ctDNA) in the 1990s. recent advances led to its introduction in the clinics. At present. the European Society Of Medical Oncology (ESMO) recommendations endorse ctDNA testing in routine clinical practice for tumor genotyping to direct molecularly targeted therapies in patients with metastatic cancer. https://balboasurfandsstylers.shop/product-category/conditioner/